DK1668036T3 - Fremgangsmåde til fremstilling af humane antistoffer, som blokerer den biologiske virkning af et humant cytokin - Google Patents

Fremgangsmåde til fremstilling af humane antistoffer, som blokerer den biologiske virkning af et humant cytokin

Info

Publication number
DK1668036T3
DK1668036T3 DK04816198.8T DK04816198T DK1668036T3 DK 1668036 T3 DK1668036 T3 DK 1668036T3 DK 04816198 T DK04816198 T DK 04816198T DK 1668036 T3 DK1668036 T3 DK 1668036T3
Authority
DK
Denmark
Prior art keywords
human
activity
preparation
block
human antibodies
Prior art date
Application number
DK04816198.8T
Other languages
English (en)
Inventor
Bernard Bizzini
Daniel Zagury
Buanec Helene Le
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs filed Critical Neovacs
Application granted granted Critical
Publication of DK1668036T3 publication Critical patent/DK1668036T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04816198.8T 2003-09-16 2004-09-15 Fremgangsmåde til fremstilling af humane antistoffer, som blokerer den biologiske virkning af et humant cytokin DK1668036T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0350543A FR2859725B1 (fr) 2003-09-16 2003-09-16 Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
PCT/FR2004/050436 WO2005028513A2 (fr) 2003-09-16 2004-09-15 Procede a haut rendement pour l’obtention d’anticorps humains neutralisant l’activite biologique d’une cytokine humaine

Publications (1)

Publication Number Publication Date
DK1668036T3 true DK1668036T3 (da) 2011-05-09

Family

ID=34203543

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04816198.8T DK1668036T3 (da) 2003-09-16 2004-09-15 Fremgangsmåde til fremstilling af humane antistoffer, som blokerer den biologiske virkning af et humant cytokin

Country Status (12)

Country Link
US (1) US8679483B2 (da)
EP (2) EP1668036B1 (da)
JP (1) JP5095210B2 (da)
CN (1) CN1882610A (da)
AT (1) ATE495756T1 (da)
CA (1) CA2539172C (da)
DE (1) DE602004031133D1 (da)
DK (1) DK1668036T3 (da)
ES (1) ES2358118T3 (da)
FR (1) FR2859725B1 (da)
IL (1) IL174356A0 (da)
WO (1) WO2005028513A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050044A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CN103180944A (zh) 2010-10-25 2013-06-26 松下电器产业株式会社 电子元件的接合方式
EP2508197A1 (en) * 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
CA2832260C (en) * 2011-04-07 2021-06-22 Neovacs Method for treating ifnalpha related conditions
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716111A (en) * 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB2218703B (en) * 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
FR2677654B1 (fr) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
CA2101148A1 (en) 1992-07-23 1994-01-24 Hugette Cohen Purification of hapten-carrier generated antibodies
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
AU6852594A (en) * 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AU3632595A (en) * 1994-09-15 1996-03-29 Verigen, Inc Porcine antibodies to tnf-alpha(alpha)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
JP3957765B2 (ja) * 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
SI2168984T1 (sl) 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
JP2001011096A (ja) * 1999-06-28 2001-01-16 Maruho Co Ltd 淋菌に対するヒト抗体
FR2812813B1 (fr) * 2000-08-09 2004-11-26 Neovacs Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
JP2002316944A (ja) * 2001-04-17 2002-10-31 Chemo Sero Therapeut Res Inst ヒトポリクローナル抗体組成物
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
FR2838444B1 (fr) 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
GB0213878D0 (en) * 2002-06-17 2002-07-31 Protherics Plc Use
DE60333228D1 (de) * 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen

Also Published As

Publication number Publication date
FR2859725A1 (fr) 2005-03-18
CA2539172C (fr) 2015-07-14
US20070202102A1 (en) 2007-08-30
EP1668036A2 (fr) 2006-06-14
JP5095210B2 (ja) 2012-12-12
CN1882610A (zh) 2006-12-20
ATE495756T1 (de) 2011-02-15
WO2005028513A3 (fr) 2005-07-21
ES2358118T3 (es) 2011-05-05
DE602004031133D1 (de) 2011-03-03
FR2859725B1 (fr) 2006-03-10
WO2005028513A2 (fr) 2005-03-31
EP2105448A2 (fr) 2009-09-30
JP2007533622A (ja) 2007-11-22
EP1668036B1 (fr) 2011-01-19
US8679483B2 (en) 2014-03-25
IL174356A0 (en) 2006-08-01
EP2105448A3 (fr) 2012-11-14
CA2539172A1 (fr) 2005-03-31

Similar Documents

Publication Publication Date Title
DK1668036T3 (da) Fremgangsmåde til fremstilling af humane antistoffer, som blokerer den biologiske virkning af et humant cytokin
ATE513905T1 (de) Verfahren für die replikation von influenza in zellkultur, und die bei diesem verfahren hergestellten influenza viren
WO2005052001A3 (en) Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
WO2004058178A3 (en) Uses of mammalian cytokine; related reagents
CR8783A (es) Anticuerpos anti-il13 y complejos
EP2371859A3 (en) Treatment of TNF alpha related disorders
WO2004085475A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
IL249263B (en) Method for ex-vivo organ care
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
NO20054959L (no) Fremgangsmater for behandling av interleukin-6 relaterte sykdommer
WO2001064749A3 (en) Method for preparing anti-mif antibodies
NO20070153L (no) Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
EA200701377A1 (ru) Имплантируемый биоматериал и способ его получения
CY1110843T1 (el) Αντισωματα εναντι il-22ra και εταιροι δεσμευσης και μεθοδοι χρησης σε φλεγμονη
EP1511618A4 (en) IMPROVED ADHESIVE MICROSTRUCTURE AND METHOD OF MANUFACTURING THE SAME
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
ATE322288T1 (de) Zusammensetzungen zur immunisierung sowie deren verwendung
ECSP077222A (es) Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
ATE344321T1 (de) Verfahren zur aufreinigung von bakterienzellen und zellbestandteilen
DE602004016522D1 (de) Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)
ATE490271T1 (de) Rezeptor, dessen verwendung sowie mausantikörper
DE69617956D1 (de) Zusammensetzungen, welche adp-ribosyltransferase-aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben
NO20044917L (no) Fremgangsmate og mellomprodukter for fremstilling av ikke-nukleoside HIV-reverstranskriptase-inhibitorer